MedPath

Curegenix Inc.

Curegenix Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Phase 1
Conditions
Gastrointestinal Cancer
Bile Duct Carcinoma
Esophageal Carcinoma
Colorectal Adenocarcinoma
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma
Hepatocellular Carcinoma
Interventions
First Posted Date
2018-04-25
Last Posted Date
2020-07-24
Lead Sponsor
Curegenix Inc.
Target Recruit Count
39
Registration Number
NCT03507998
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Phase 1
Conditions
Solid Tumors
GI Cancer
Interventions
First Posted Date
2016-02-05
Last Posted Date
2022-01-26
Lead Sponsor
Curegenix Inc.
Target Recruit Count
72
Registration Number
NCT02675946
Locations
🇺🇸

Memorial Care, Long Beach, California, United States

🇺🇸

St. Joseph's Santa Rosa, Santa Rosa, California, United States

🇺🇸

Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

and more 22 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.